Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice (2008)

Peer-Reviewed Study · Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M · August 12, 2008

Chen Q et al., 2008-08-12: Mouse xenograft study showing that parenteral (not oral) ascorbate generates hydrogen peroxide selectively in tumor interstitial fluid and slows established ovarian, pancreatic and glioblastoma tumours.

a regimen of daily pharmacologic ascorbate treatment significantly decreased growth rates of ovarian (P < 0.005), pancreatic (P < 0.05), and glioblastoma (P < 0.001) tumors established in mice.

Abstract (PNAS 105(32):11105-11109)

Chen Q et al., 2008-08-12: Mouse xenograft study showing that parenteral (not oral) ascorbate generates hydrogen peroxide selectively in tumor interstitial fluid and slows established ovarian, pancreatic and glioblastoma tumours. The 'Chen et al. 2008' paper the claim names; the earlier Chen paper is PNAS 2005 (PMID 16157892) and is a different study. Funder: NIH intramural (NIDDK Laboratory of Bioorganic Chemistry and NCI Radiation Biology Branch); disclosed conflict: 'The authors declare no conflict of interest'; no commercial product or maker tested (pharmacologic ascorbate); comparator: untreated/saline-treated mice. Animal data only: no human tumour-response endpoint in this paper. PMCID PMC2516281.